Not a member? To register
Fujifilm Corp. (Tokyo) announced a $1. 2 billion investment in its large-scale mobile culture CDMO business to further expand FUJIFILM Diosynth Biotechnologies’ planned end-to-end bioproduction facility in Holly Springs, North Carolina, bringing the overall investment in the facility to more than $3. 2 billion. This expansion adds large-scale production capacity to FUJIFILM Diosynth Biotechnologies’ global network at its U. S. production sites. Europa. La The U. S. investment will generate an additional 680 jobs through 2031, which will also bring the total number of new high-skilled local jobs to 1,400 in Holly Springs.
The new investment in FUJIFILM Diosynth Biotechnologies’ large-scale mobile culture facility in Holly Springs will add 8 x 20,000 liter (L) mobile mammalian culture bioreactors by 2028, to the 8 x 20,000 L already planned for the bulk drug in the initial period. This new facility allows flexibility to expand with more bioreactors to accommodate new projects that meet the emerging desires of spouses and, when completed, will be one of the largest CDMO mobile biopharmaceutical culture facilities in North America.
The strategic investment and expansion support a key pillar of FUJIFILM Diosynth Biotechnologies’ Partners for Life strategy, which consists of large-scale production functions at U. S. sites. We use the U. S. and Europe to meet the end-to-end desires of biopharmaceutical consumers and the supply chain. resilience. Using FUJIFILM Diosynth Biotechnologies’ modular production model, KojoXTM, this expansion allows the company to build the same large-scale production facilities in the U. S. and Canada. We are working to ensure that consumers can seamlessly integrate drug production, regardless of their location.
“This investment is a step to further drive the expansion of our biopharmaceutical CDMO business,” said Teiichi Goto, Chief Executive Officer and Representative Director of FUJIFILM Corporation. “Fujifilm is committed to promoting a healthier society and we are proud that our other people and these Holly Springs facilities play a critical role in helping our partners produce life-saving treatments to meet the needs of patients.
“The new jobs created through the expansion of FUJIFILM Diosynth Biotechnologies in Wake County are an example of the thriving economic relationship between North Carolina and Japan, and we are grateful for their continued investments in our state,” said Governor Cooper of North Carolina. Corporations continue to provide good-paying jobs and economic opportunity for the rest of the people of North Carolina. “
“We are pleased to continue to invest in expanding our mobile culture production capabilities in North Carolina, in anticipation of the growing outsourcing desires of biopharmaceutical companies,” said Toshihisa Iida, Vice President of FUJIFILM Corporation and President of FUJIFILM Diosynth Biotechnologies. “North Carolina continues to deliver advantageous and well-established benefits to Fujifilm’s bioproduction business, such as sustainable energy resources, infrastructure for long-term growth, and a strong pipeline of technical talent.
The antibody drugs market is expected to grow at an annual rate of 8% through 2030*2 due to the increasing demand for traditional antibody drugs, as well as the expansion of antibody-drug conjugates (ADCs) and new bispecific antibodies.
“Ensuring a good enough capacity to meet the demands of market position is a cornerstone of our Partners for Life strategy and is critical to helping our partners bring life-impacting medicines to patients,” said Lars Petersen, President and CEO of FUJIFILM Diosynth Biotechnologies. “As we build our new biomanufacturing facility, we are grateful to our partners, adding Governor Cooper, the State of North Carolina and the City of Holly Springs. The City of Holly Springs and the State of North Carolina in combination have created an ideal environment for expansion and progress through their strategic investments in water, sewer and road infrastructure, making it an ideal position for us to grow here.
Consistent with the overall design and structure of the Holly Springs facility, the investment announced today will incorporate sustainability projects that contribute to net zero operations. All energy needs for operations are expected to be 100 percent offset through the use of renewable landfill gas, on-site sunshine and the 125,000 MWh of annual sustainable sunshine from a virtual power procurement agreement. Additional sustainability goals for water and waste relief align with Fujifilm’s 2030 Sustainable Value Plan, and the campus is on track to achieve LEED Gold certification with projects including water diversion, 90% of structural waste from landfills and more solar energy on the roof. and the installation of a heat recovery chiller. systems to maximize power between boilers and chilled water system, use of low embodied carbon waste concrete fly ash providing 10% relief in carbon emissions compared to popular cement system and the installation of ultra-low nitrogen oxide boilers, leading to a 50% relief of nitrogen emissions.
The allocation of FUJIFILM Diosynth Biotechnologies in North Carolina will be facilitated, in part, through an Employment Development Investment Grant (JDIG) through the state’s Economic Investment Committee today. Over the 12 years of this grant, the allocation is expected to generate $4. 7 billion in state economic growth.
Chemical engineering and content published weekly.